What happened
INVO Fertility, Inc. (NASDAQ: IVF) lifted clinic revenue 28% to $2.21 million from $1.72 million in the third quarter. That is $485,364 more than a year earlier.
Total revenue rose 26% to $2.22 million from $1.76 million. Net loss narrowed to $2.1 million from $3.4 million.
For holders, the clinics are still adding sales while losses shrink. The company is not yet profitable as a whole.
INVO Fertility has four operating fertility clinics in the United States. It plans to build, acquire and run fertility clinics and related businesses and technologies. It also still sells INVOcell to third-party clinics.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
Why it matters
Loss from operations improved to $1.5 million from $1.6 million. Consolidated Adjusted EBITDA was a loss of $1.0 million, versus a loss of $0.9 million a year earlier.
Corporate overhead still kept consolidated Adjusted EBITDA negative.
Clinic-Level Adjusted EBITDA stayed positive for the seventh straight quarter at $292,114, up from $243,120.
That clinic profit has to cover corporate costs before the company can turn a consolidated profit. It does not yet.
The company said the planned Birmingham acquisition transition cut clinic-level contribution by about $193,000.
Management said new tools are being rolled out across its practices to cut time spent on documentation and administrative work. It expects them to improve patient experience and clinic-level efficiency.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
Where the growth came from
Management said revenue grew at the Wisconsin and Atlanta clinics. It said Wisconsin joined the Progyny network in the first quarter, which widened access for patients with Progyny coverage.
The Indiana clinic, acquired in February, and the Birmingham clinic, acquired in late June, each added a full quarter of revenue.
Product revenue fell to $15,069 from $34,871. Sales to Indiana and Birmingham were eliminated once those clinics became consolidated subsidiaries.
INVO Fertility said it attended the American Society for Reproductive Medicine Scientific Congress Expo in Baltimore in October 2026. It said the meeting led to more potential acquisition opportunities.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.
Balance sheet and liquidity
Cash was $3.70 million at Sept. 30. Current liabilities were $4.46 million, down from $10.33 million at Dec. 31, 2025.
The balance sheet is cleaner than at year-end, but cash still trails near-term obligations.
INVO Fertility said assets rose $5.3 million and liabilities fell $5.5 million. Net equity reached $18.0 million, or $15.09 per share.
The company had 1,192,860 shares of common stock outstanding as of Nov. 13, 2026.
Explain the financial terms
A balance sheet shows a company's assets, debts and owners' equity at a point in time.
What's next
INVO Fertility will host a webcast on Monday, Nov. 16, 2026, at 11:00 a.m. Eastern Time to discuss third-quarter results and give a business update.
Clinic growth that continues without leaning so heavily on acquisitions would strengthen the case. Another quarter of negative companywide Adjusted EBITDA would leave the turnaround unfinished.
Explain the financial terms
A fiscal quarter is a three-month period in the company's reporting year.

